Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.70 |
| ▸ | HTR1A | P08908 | 1/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.70 |
| ▸ | ACHE | P22303 | 4/20 | 0.65 |
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.54 |
| ▸ | HTR2B | P41595 | 2/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.54 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5659132 | 0.99 | HTR2A (0.69) | HTR2AHTR1ATMEM97ACHEPARP1 | |
| SCHEMBL5660772 | 0.90 | ACHE (0.78) | HTR2AHTR1ATMEM97ACHEPARP1 | |
| Hydrochloric Acid SCHEMBL5656521 | 0.89 | ACHE (0.76) | HTR2AHTR1ATMEM97ACHEPARP1 | |
| SCHEMBL5660124 | 0.89 | HTR2A (0.67) | HTR2AHTR1ATMEM97ACHE | |
| Hydrochloric Acid SCHEMBL5657727 | 0.88 | HTR2A (0.66) | HTR2AHTR1ATMEM97ACHE | |
| SCHEMBL5655952 | 0.82 | HTR2A (0.81) | HTR2AHTR1ATMEM97ACHEPARP1 | |
| Roluperidone SCHEMBL5252391 | 0.82 | HTR2A (1.00) | HTR2AHTR1ATMEM97ACHEPARP1 | |
| SCHEMBL5660164 | 0.82 | HTR2A (0.65) | HTR2AHTR1ATMEM97ACHEDRD2 | |
| Hydrochloric Acid SCHEMBL5660374 | 0.81 | HTR2A (0.64) | HTR2AHTR1ATMEM97ACHEDRD2 | |
| SCHEMBL5255035 | 0.81 | HTR2A (0.64) | HTR2AHTR1ATMEM97ACHEDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR2A 153/4885HTR1A 79/4885TMEM97 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.